• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Concordia Details Long-Term Growth Strategy

    Bryan Mc Govern
    Sep. 06, 2017 09:19AM PST
    Pharmaceutical Investing

    Concordia outlined their growth strategy in Europe.

    Concordia (NASDAQ:CXRX; TSX:CXR) outlined their strategy for their growth in Europe.
    As quoted in the press release:

    “At its essence, the DELIVER strategy will focus Concordia’s efforts on becoming a leading European specialty `off-patent’ medicines player,” said Concordia Chief Executive Officer Allan Oberman. “The development of this strategy was a multi-month initiative that was done internally, reflecting contributions from more than 50 Concordia employees including our senior management team, and our board of directors. It is the culmination of a holistic team effort that we are very excited about.”
    Senior management and Concordia’s board of directors believe the name DELIVER is appropriate for this strategy because it is precisely what the Company intends to do, and it is an acronym that, letter by letter, defines the critical elements of the strategy.

    Click here to read the full press release.

    Source: www.newswire.ca

    pharmaceutical investingcritical elementseuropeboard of directors
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Canada maple leaves on left and pharmaceutical pills in red and blue on right.

    5 Best-performing Canadian Pharma Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
      • Electric Vehicles
    • Agriculture
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Energy
      • Uranium
      • Oil and Gas
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Robotics
      • Crypto
      • Cleantech
    Life Science
      • Biotech
      • Cannabis
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES